🔗 Permalink

Inventor profile of:

Hiroshi Shiku

City:

Tsu

Country:

Japan

Published Applications:

22

Last publication date:

2023-11-02

Top Assignees for applications by Hiroshi Shiku

The entities that hold a legal rights for patent applications filed by inventor Shiku Hiroshi:

MIE UNIVERSITY 8 Tsu, Japan
MIE UNIVERSITY 7 Mie, Japan
MIE UNIVERSITY 6 Tsu-shi, Japan
TAKARA BIO INC. 6 Shiga, Japan
TAKARA BIO INC. 5 Otsu-shi, Japan
KYOTO UNIVERSITY 3 Kyoto, Japan
MIE UNIVERSITY 2 Tsu-shi, Mie, Japan
DAIICHI SANKYO COMPANY, LIMITED 2 Tokyo, Japan
TAKARA BIO INC. 1 Otsu-shi, Shiga, Japan
GENERAL INCORPORATED ASSOCIATION PHARMA VALLEY PROJECT SUPPORTING ORGANIZATION 1 Mishima-shi, Japan
KABUSHIKI KAISHA YAKULT HONSHA 1 Minato-ku, Japan
Immunofrontier, Inc. 1 Tsu-Shi, Japan
GENERAL INCORPORATED ASSOCIATION PHARMA VALLEY PROJECT SUPPORTING ORGANIZATION 1 Mishima, Japan

Recent patent applications by Shiku Hiroshi

Hiroshi Shiku from Tsu, JP has applied for patents for these inventions. The list has both pending applications and granted patents:

#1 | 2023-11-02

US20230348616A1

Chemistry; metallurgy

BISPECIFIC ANTIBODY

#2 | 2023-09-14

US20230287121A1

Chemistry; metallurgy

Bispecific antibody

#3 | 2023-06-29

US20230201263A1

Human necessities

PRETREATMENT DRUG FOR T CELL INFUSION THERAPY FOR IMMUNE-CHECKPOINT INHIBITOR-RESISTANT TUMOR

#4 | 2021-08-05

US20210239664A1

Exosome production method

#5 | 2021-06-03

US20210161963A1

Human necessities

METHOD FOR GENE TRANSFER INTO GAMMA-DELTA TYPE T CELL

#6 | 2020-11-19

US20200360435A1

Human necessities

T-CELL RECEPTOR

#7 | 2020-09-03

US20200276237A1

Human necessities

Antigen-binding protein that recognizes MAGE-A4-derived peptide

#8 | 2019-02-07

US20190038645A1

Human necessities

Agent for overcoming immunosuppression and use thereof

#9 | 2019-01-17

US20190015490A1

Human necessities

Long chain antigen containing interepitope sequence that promotes antigen presentation to T cells

#10 | 2018-06-28

US20180177816A1

Human necessities

Therapeutic agent associated with suppression of proliferation and metastasis of tumor, which comprises exosomes released from cytotoxic T cells and targets cancer stromal/mesenchymal cells

#11 | 2016-01-21

US20160015751A1

Human necessities

Method for enhancing a function of a T cell

#12 | 2015-08-20

US20150232530A1

Chemistry; metallurgy

Method for expression of specific gene

#13 | 2014-05-01

US20140120124A1

Human necessities

Cell capable of expressing exogenous GITR ligand

#14 | 2013-05-09

US20130115199A1

Chemistry; metallurgy

T-cell receptor and nucleic acid encoding the receptor

#15 | 2012-09-20

US20120238012A1

Chemistry; metallurgy

Cytotoxic T lymphocyte

#16 | 2011-12-29

US20110318839A1

Human necessities

Method for enhancing a function of a T cell

#17 | 2011-10-20

US20110256114A1

Human necessities

T-cell receptor and nucleic acid encoding the receptor

#18 | 2011-10-13

US20110250230A1

Human necessities

Cell capable of expressing exogenous GITR ligand

#19 | 2010-10-28

US20100273213A1

Chemistry; metallurgy

Method for expression of specific gene

#20 | 2009-12-31

US20090324566A1

Human necessities

T-cell receptor and nucleic acid encoding the receptor

#21 | 2009-03-12

US20090068209A1

Chemistry; metallurgy

Cytotoxic T lymphocyte

#22 | 2008-08-19

US10746747

Vaccine comprising a polynucleotide encoding an antigen recognized by a CD4helper T-cell and a polynucleotide encoding a tumor specific or associated antigen recognized by a CD8CTL

InventorID:

6019983 ⎘